0001434265 gmab:PropertiesMember 2024-06-30 0001434265 gmab:PropertiesMember 2023-12-31 0001434265 gmab:TepezzaMember 2024-04-01 2024-06-30 0001434265 gmab:OtherRoyaltyProductMember 2024-04-01 2024-06-30 0001434265 gmab:KesimptaMember 2024-04-01 2024-06-30 0001434265 gmab:DarzalexMember 2024-04-01 2024-06-30 0001434265 gmab:TepezzaMember 2024-01-01 2024-06-30 0001434265 gmab:OtherRoyaltyProductMember 2024-01-01 2024-06-30 0001434265 gmab:KesimptaMember 2024-01-01 2024-06-30 0001434265 gmab:DarzalexMember 2024-01-01 2024-06-30 0001434265 gmab:TepezzaMember 2023-04-01 2023-06-30 0001434265 gmab:OtherRoyaltyProductMember 2023-04-01 2023-06-30 0001434265 gmab:KesimptaMember 2023-04-01 2023-06-30 0001434265 gmab:DarzalexMember 2023-04-01 2023-06-30 0001434265 gmab:TepezzaMember 2023-01-01 2023-06-30 0001434265 gmab:OtherRoyaltyProductMember 2023-01-01 2023-06-30 0001434265 gmab:KesimptaMember 2023-01-01 2023-06-30 0001434265 gmab:DarzalexMember 2023-01-01 2023-06-30 0001434265 gmab:RoyaltiesRevenueMember 2024-04-01 2024-06-30 0001434265 gmab:ReimbursementIncomeMember 2024-04-01 2024-06-30 0001434265 gmab:NetProductSalesMember 2024-04-01 2024-06-30 0001434265 gmab:CollaborationRevenueMember 2024-04-01 2024-06-30 0001434265 gmab:RoyaltiesRevenueMember 2024-01-01 2024-06-30 0001434265 gmab:ReimbursementIncomeMember 2024-01-01 2024-06-30 0001434265 gmab:NetProductSalesMember 2024-01-01 2024-06-30 0001434265 gmab:MilestonePaymentsRevenueMember 2024-01-01 2024-06-30 0001434265 gmab:CollaborationRevenueMember 2024-01-01 2024-06-30 0001434265 gmab:RoyaltiesRevenueMember 2023-04-01 2023-06-30 0001434265 gmab:ReimbursementIncomeMember 2023-04-01 2023-06-30 0001434265 gmab:NetProductSalesMember 2023-04-01 2023-06-30 0001434265 gmab:MilestonePaymentsRevenueMember 2023-04-01 2023-06-30 0001434265 gmab:CollaborationRevenueMember 2023-04-01 2023-06-30 0001434265 gmab:RoyaltiesRevenueMember 2023-01-01 2023-06-30 0001434265 gmab:ReimbursementIncomeMember 2023-01-01 2023-06-30 0001434265 gmab:NetProductSalesMember 2023-01-01 2023-06-30 0001434265 gmab:MilestonePaymentsRevenueMember 2023-01-01 2023-06-30 0001434265 gmab:CollaborationRevenueMember 2023-01-01 2023-06-30 0001434265 ifrs-full:GrossCarryingAmountMember gmab:NonAmortizedIntangibleAssetsMember gmab:IfrsInProcessResearchAndDevelopmentMember 2024-06-30 0001434265 ifrs-full:GrossCarryingAmountMember gmab:AmortizedIntangibleAssetsMember ifrs-full:TechnologybasedIntangibleAssetsMember 2024-06-30 0001434265 ifrs-full:GrossCarryingAmountMember gmab:AmortizedIntangibleAssetsMember gmab:LicensesAndPatentsMember 2024-06-30 0001434265 ifrs-full:AccumulatedImpairmentMember gmab:AmortizedIntangibleAssetsMember gmab:LicensesAndPatentsMember 2024-06-30 0001434265 ifrs-full:AccumulatedDepreciationAndAmortisationMember gmab:AmortizedIntangibleAssetsMember ifrs-full:TechnologybasedIntangibleAssetsMember 2024-06-30 0001434265 ifrs-full:AccumulatedDepreciationAndAmortisationMember gmab:AmortizedIntangibleAssetsMember gmab:LicensesAndPatentsMember 2024-06-30 0001434265 ifrs-full:GrossCarryingAmountMember gmab:AmortizedIntangibleAssetsMember 2024-06-30 0001434265 ifrs-full:AccumulatedImpairmentMember gmab:AmortizedIntangibleAssetsMember 2024-06-30 0001434265 ifrs-full:AccumulatedDepreciationAndAmortisationMember gmab:AmortizedIntangibleAssetsMember 2024-06-30 0001434265 gmab:NonAmortizedIntangibleAssetsMember gmab:IfrsInProcessResearchAndDevelopmentMember 2024-06-30 0001434265 gmab:AmortizedIntangibleAssetsMember ifrs-full:TechnologybasedIntangibleAssetsMember 2024-06-30 0001434265 gmab:AmortizedIntangibleAssetsMember gmab:LicensesAndPatentsMember 2024-06-30 0001434265 ifrs-full:GrossCarryingAmountMember 2024-06-30 0001434265 ifrs-full:AccumulatedImpairmentMember 2024-06-30 0001434265 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2024-06-30 0001434265 gmab:AmortizedIntangibleAssetsMember 2024-06-30 0001434265 ifrs-full:GrossCarryingAmountMember gmab:AmortizedIntangibleAssetsMember gmab:LicensesAndPatentsMember 2023-12-31 0001434265 ifrs-full:AccumulatedDepreciationAndAmortisationMember gmab:AmortizedIntangibleAssetsMember gmab:LicensesAndPatentsMember 2023-12-31 0001434265 gmab:AmortizedIntangibleAssetsMember gmab:LicensesAndPatentsMember 2023-12-31 0001434265 ifrs-full:GrossCarryingAmountMember 2023-12-31 0001434265 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2023-12-31 0001434265 ifrs-full:SharePremiumMember 2024-01-01 2024-06-30 0001434265 ifrs-full:SharePremiumMember 2023-01-01 2023-06-30 0001434265 gmab:ProfoundbioMember ifrs-full:TechnologybasedIntangibleAssetsMember 2024-05-21 0001434265 gmab:ProfoundbioMember gmab:IfrsInProcessResearchAndDevelopmentMember 2024-05-21 0001434265 gmab:ProfoundbioMember 2023-12-31 0001434265 gmab:OtherInvestmentMember ifrs-full:Level3OfFairValueHierarchyMember 2024-06-30 0001434265 gmab:OtherInvestmentMember ifrs-full:Level2OfFairValueHierarchyMember 2024-06-30 0001434265 gmab:OtherInvestmentMember ifrs-full:Level1OfFairValueHierarchyMember 2024-06-30 0001434265 gmab:MarketableSecuritiesMember ifrs-full:Level1OfFairValueHierarchyMember 2024-06-30 0001434265 gmab:OtherInvestmentMember 2024-06-30 0001434265 gmab:MarketableSecuritiesMember 2024-06-30 0001434265 gmab:OtherInvestmentMember ifrs-full:Level3OfFairValueHierarchyMember 2023-12-31 0001434265 gmab:OtherInvestmentMember ifrs-full:Level1OfFairValueHierarchyMember 2023-12-31 0001434265 gmab:MarketableSecuritiesMember ifrs-full:Level1OfFairValueHierarchyMember 2023-12-31 0001434265 gmab:OtherInvestmentMember 2023-12-31 0001434265 gmab:MarketableSecuritiesMember 2023-12-31 0001434265 ifrs-full:SharePremiumMember 2024-06-30 0001434265 ifrs-full:RetainedEarningsMember 2024-06-30 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-06-30 0001434265 ifrs-full:IssuedCapitalMember 2024-06-30 0001434265 ifrs-full:SharePremiumMember 2023-12-31 0001434265 ifrs-full:RetainedEarningsMember 2023-12-31 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-12-31 0001434265 ifrs-full:IssuedCapitalMember 2023-12-31 0001434265 ifrs-full:SharePremiumMember 2023-06-30 0001434265 ifrs-full:RetainedEarningsMember 2023-06-30 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-06-30 0001434265 ifrs-full:IssuedCapitalMember 2023-06-30 0001434265 ifrs-full:SharePremiumMember 2022-12-31 0001434265 ifrs-full:RetainedEarningsMember 2022-12-31 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-12-31 0001434265 ifrs-full:IssuedCapitalMember 2022-12-31 0001434265 gmab:PropertiesMember 2024-04-01 2024-06-30 0001434265 gmab:PropertiesMember 2024-01-01 2024-06-30 0001434265 gmab:PropertiesMember 2023-04-01 2023-06-30 0001434265 gmab:PropertiesMember 2023-01-01 2023-06-30 0001434265 ifrs-full:RetainedEarningsMember 2024-01-01 2024-06-30 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-01-01 2024-06-30 0001434265 ifrs-full:RetainedEarningsMember 2023-01-01 2023-06-30 0001434265 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-01-01 2023-06-30 0001434265 gmab:ProfoundbioMember 2024-01-01 2024-06-30 0001434265 gmab:IfrsInProcessResearchAndDevelopmentMember 2024-01-01 2024-06-30 0001434265 gmab:ProfoundbioMember 2024-05-20 2024-05-20 0001434265 gmab:IfrsRestrictedStockUnitsRSUsMember 2024-01-01 2024-06-30 0001434265 gmab:IfrsRestrictedStockUnitsRSUsMember 2023-01-01 2023-06-30 0001434265 2021-01-01 2021-06-30 0001434265 srt:MaximumMember gmab:StockRepurchaseAuthorization2024Member 2024-03-13 2024-03-13 0001434265 gmab:PfizerMember 2024-04-01 2024-06-30 0001434265 gmab:NovartisMember 2024-04-01 2024-06-30 0001434265 gmab:AgreementsWithRocheMember 2024-04-01 2024-06-30 0001434265 gmab:AgreementsWithJanssenMember 2024-04-01 2024-06-30 0001434265 gmab:AgreementsWithBointechMember 2024-04-01 2024-06-30 0001434265 gmab:AgreementsWithAbbvieMember 2024-04-01 2024-06-30 0001434265 gmab:PfizerMember 2024-01-01 2024-06-30 0001434265 gmab:NovartisMember 2024-01-01 2024-06-30 0001434265 gmab:AgreementsWithRocheMember 2024-01-01 2024-06-30 0001434265 gmab:AgreementsWithJanssenMember 2024-01-01 2024-06-30 0001434265 gmab:AgreementsWithBointechMember 2024-01-01 2024-06-30 0001434265 gmab:AgreementsWithAbbvieMember 2024-01-01 2024-06-30 0001434265 gmab:PfizerMember 2023-04-01 2023-06-30 0001434265 gmab:NovartisMember 2023-04-01 2023-06-30 0001434265 gmab:AgreementsWithRocheMember 2023-04-01 2023-06-30 0001434265 gmab:AgreementsWithJanssenMember 2023-04-01 2023-06-30 0001434265 gmab:AgreementsWithBointechMember 2023-04-01 2023-06-30 0001434265 gmab:AgreementsWithAbbvieMember 2023-04-01 2023-06-30 0001434265 gmab:PfizerMember 2023-01-01 2023-06-30 0001434265 gmab:NovartisMember 2023-01-01 2023-06-30 0001434265 gmab:AgreementsWithRocheMember 2023-01-01 2023-06-30 0001434265 gmab:AgreementsWithJanssenMember 2023-01-01 2023-06-30 0001434265 gmab:AgreementsWithBointechMember 2023-01-01 2023-06-30 0001434265 gmab:AgreementsWithAbbvieMember 2023-01-01 2023-06-30 0001434265 gmab:DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember 2024-01-01 2024-06-30 0001434265 2022-12-31 0001434265 currency:USD ifrs-full:CurrencyRiskMember 2024-06-30 0001434265 currency:GBP ifrs-full:CurrencyRiskMember 2024-06-30 0001434265 currency:EUR ifrs-full:CurrencyRiskMember 2024-06-30 0001434265 currency:DKK ifrs-full:CurrencyRiskMember 2024-06-30 0001434265 gmab:TripleaRatingMember ifrs-full:CreditRiskMember 2024-06-30 0001434265 ifrs-full:CurrencyRiskMember 2024-06-30 0001434265 currency:USD ifrs-full:CurrencyRiskMember 2023-12-31 0001434265 currency:GBP ifrs-full:CurrencyRiskMember 2023-12-31 0001434265 currency:EUR ifrs-full:CurrencyRiskMember 2023-12-31 0001434265 currency:DKK ifrs-full:CurrencyRiskMember 2023-12-31 0001434265 gmab:TripleaRatingMember ifrs-full:CreditRiskMember 2023-12-31 0001434265 ifrs-full:CurrencyRiskMember 2023-12-31 0001434265 ifrs-full:WarrantsMember 2024-01-01 2024-06-30 0001434265 ifrs-full:WarrantsMember 2023-01-01 2023-06-30 0001434265 2023-06-30 0001434265 2021-06-30 0001434265 2024-03-15 2024-03-15 0001434265 2024-02-14 2024-02-14 0001434265 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2024-01-01 2024-06-30 0001434265 2024-06-30 0001434265 2023-12-31 0001434265 2024-04-01 2024-06-30 0001434265 2023-04-01 2023-06-30 0001434265 gmab:MijkeZachariasseMartinSchultzAndTakahiroHamataniMember 2024-01-01 2024-06-30 0001434265 gmab:ProfoundbioMember 2024-05-21 0001434265 gmab:ProfoundbioMember 2024-06-30 0001434265 gmab:ProfoundbioMember 2024-05-21 2024-05-21 0001434265 2023-01-01 2023-06-30 0001434265 gmab:ProfoundbioMember 2024-05-21 2024-06-30 0001434265 2024-01-01 2024-06-30 iso4217:DKK gmab:item iso4217:USD gmab:director gmab:patent shares pure iso4217:DKK shares iso4217:DKK iso4217:USD Genmab A/S 0001434265 6-K 2024-06-30 false --12-31 Q2 2024 P1Y

5402000000

4169000000

9545000000

7003000000

190000000

21000000

375000000

21000000

2502000000

1853000000

4801000000

3594000000

894000000

827000000

1676000000

1503000000

176000000

252000000

3762000000

2701000000

7104000000

5118000000

1640000000

1468000000

2441000000

1885000000

886000000

346000000

1993000000

738000000

399000000

120000000

591000000

663000000

2127000000

1694000000

3843000000

1960000000

719000000

359000000

1110000000

415000000

1408000000

1335000000

2733000000

1545000000

126000000

-5000000

174000000

14000000

1534000000

1330000000

2907000000

1559000000

21.85

20.46

42.13

23.66

21.70

20.28

41.85

23.45

12011000000

101000000

952000000

955000000

928000000

686000000

77000000

62000000

212000000

196000000

134000000

2518000000

16682000000

2150000000

36000000

57000000

6168000000

4947000000

11402000000 13268000000

4331000000

14867000000

21937000000

33139000000

38619000000

35289000000

66000000

12536000000

12461000000

234000000

60000000

18133000000

19023000000

30969000000

31610000000

925000000

680000000

480000000

1853000000

28000000

35000000

3286000000

1195000000

837000000

54000000

94000000

90000000

33000000

3400000000

2307000000

4364000000

2484000000

7650000000

3679000000

38619000000

35289000000

3843000000

1960000000

1993000000

738000000

591000000

663000000

349000000

271000000

160000000

125000000

26000000

27000000

64000000

-1049000000

1270000000

21000000

-51000000

758000000

171000000

2770000000 3698000000

596000000

384000000

-16000000 -11000000

-324000000

-400000000

3026000000

3671000000

12246000000

79000000

10000000

55000000

201000000

5237000000

7112000000

7437000000

5490000000

33000000

15000000

-10213000000

-1848000000

75000000

103000000

43000000

50000000

3585000000 564000000 93000000 93000000

-3646000000

-604000000

-10833000000

1219000000

14867000000

9893000000

297000000

-238000000

4331000000

10874000000

4318000000

10240000000

13000000

634000000

4331000000

10874000000

66000000

12309000000

98000000

14809000000

27282000000

1545000000

14000000

1545000000

1559000000

103000000

564000000

271000000

-93000000

66000000

12412000000

112000000

15968000000

28558000000

66000000

12461000000

60000000

19023000000

31610000000

2733000000

174000000

2733000000

2907000000

75000000

3879000000

349000000

-93000000

66000000

12536000000

234000000

18133000000

30969000000

Note 1 – Basis of PresentationAccounting PoliciesThese interim statements of the Genmab Group (Genmab or the Company) have been prepared in accordance with IAS 34 (Interim Financial Reporting) as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been audited by Genmab’s external auditors.The interim report has been prepared using the same accounting policies as outlined in Section 1 – Basis of Presentation in the financial statements in the Genmab 2023 Annual Report (Annual Report). A number of amended standards became applicable for the current reporting period. There was no impact to Genmab’s financial statements as a result of adopting these amended standards. These interim financial statements should be read in conjunction with the Annual Report.The below accounting policies have been implemented upon Genmab completing the acquisition of ProfoundBio, Inc. (ProfoundBio) on May 21, 2024.Business CombinationsThe acquisition method of accounting is used to account for all acquisitions where the target company meets the definition of a business in accordance with IFRS 3 (Business Combinations). The purchase price for a business is comprised of the fair value of the assets transferred and liabilities owned to the former owners, including option holders, of the acquired business and the fair value of any asset or liability resulting from a contingent consideration arrangement. Any amount of the purchase price which effectively comprises a settlement of a pre-existing relationship is not part of the exchange for the acquiree and is therefore not included in the consideration for the purpose of applying the acquisition method. Settlements of pre-existing relationships are accounted for as separate transactions in accordance with the relevant IFRS standards. Identifiable assets and liabilities and contingent liabilities assumed are measured at fair value on the date of acquisition by applying relevant valuation methods. Acquisition-related charges are expensed as incurred and included in Acquisition and integration related charges. Goodwill is recognized as the excess of purchase price over the fair value of net identifiable assets acquired and liabilities assumed.Other Intangible AssetsDefinite-Lived and IPR&D Intangible AssetsIntangible assets acquired in a business combination are recognized at fair value at the acquisition date. Intangible assets with definite useful lives are amortized based on the straight-line method over their estimated useful lives and reviewed for impairment if certain events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Amortization commences for in-process research and development (IPR&D) intangible assets after regulatory approval has been obtained or when assets are put in use. IPR&D intangible assets are tested for impairment at least annually or when a triggering event occurs that could indicate a potential impairment. Impairments of intangible assets are reviewed at each reporting date for possible reversal.GoodwillGoodwill represents the excess of purchase price over the fair value of net identifiable assets acquired and liabilities assumed in a business combination accounted for by the acquisition method of accounting and is not amortized, but is subject to impairment testing. Goodwill is allocated to each of the group’s cash-generating units (or groups of cash-generating units) expected to benefit from the synergies of the combination. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that the fair value of net assets in a cash-generating unit are below their carrying amounts. Quantitative goodwill impairment tests are based on management’s projections and the anticipated net present value of estimated future cash flows from marketable products. If the carrying amount of goodwill exceeds the recoverable amount, which is determined based on discounted projected cash flows, any impairment is measured as the difference between those discounted projected cash flows and the carrying amount. Impairments of goodwill are prohibited from future reversals.Management Judgements and Estimates under IFRS Accounting StandardsIn preparing interim reports, certain provisions under IFRS Accounting Standards (IFRS) require management to make judgements (various accounting estimates and assumptions), which may significantly impact Genmab’s financial statements. The interim report has been prepared using the same judgments and estimates as outlined in Section 1 – Basis of Presentation in the financial statements in the Annual Report. For a description of significant judgements and estimates, refer to Note 1.3 in the Annual Report. Additionally, upon Genmab completing the acquisition of ProfoundBio on May 21, 2024, management has determined that the below estimates related to intangible assets are an area that require significant judgement. Refer below for further information on the key accounting estimates related to the valuation of intangible assets utilized in preparation of the consolidated financial statements.Fair Value of Intangible Assets in a Business CombinationThe application of the acquisition method involves the use of significant estimates because the identifiable net assets of the acquiree are recognized at their fair values for which observable market prices are typically not available. This is particularly relevant for intangible assets which require use of valuation techniques typically based on estimates of present value of future uncertain cash flows. The significant assumptions used to estimate the value of the acquired intangible assets include discount rates and certain assumptions that form the basis of future cash flows (such as probabilities of technical and commercial success, revenue growth rates, operating margins, and royalty rates). Impairment Assessment of Intangible Assets and GoodwillIf circumstances or changes in Genmab’s operations indicate that the carrying amount of intangible assets, including goodwill, may not be recoverable, management reviews the asset for impairment. The basis for the review is the recoverable amount of the intangible asset, determined as the greater of the fair value less cost to sell or its value in use. Value in use is calculated as the net present value of future cash inflow generated from the intangible asset. If the carrying amount of an intangible asset is greater than the recoverable amount, the intangible asset is written down to the recoverable amount. An impairment loss is recognized in the income statement when the impairment is identified. Impairments on intangible assets (excluding goodwill) are reviewed at each reporting date for possible reversal.Factors considered material that could trigger an impairment test include the following:• Development of a competing drug • Realized sales trending below predicted sales • Inconsistent or unfavorable clinical readouts • Changes in the legal framework covering patents, rights and licenses • Advances in medicine and/or technology that affect the medical treatments • Adverse impact on reputation and/or brand names • Relationship to other intangible assets or property, plant and equipment Impairments of intangible assets are recognized in the Consolidated Income Statements as research and development expenses.Information about Geographical AreasGenmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates, product sales or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.Reclassifications and RevisionsTo facilitate comparison of information across periods, certain immaterial reclassifications and revisions have been made to prior period amounts to conform to the current period’s presentation. Refer to Note 1.4 in the Annual Report for further details.

Note 2 – Acquisition of BusinessesOn May 21, 2024 (Acquisition Date), Genmab completed the previously announced acquisition of all of the outstanding shares of ProfoundBio, resulting in ProfoundBio becoming a wholly-owned subsidiary of Genmab. The acquisition of ProfoundBio gave Genmab worldwide rights to three candidates in clinical development, including ProfoundBio’s lead drug candidate, rinatabart sesutecan (Rina-S). In addition, Genmab acquired ProfoundBio’s novel ADC technology platforms. Rina-S is a clinical-stage, FRα-targeted, TOPO1 ADC, currently in Phase 2 of a Phase 1/2 clinical trial, for the treatment of ovarian cancer and other FRα-expressing solid tumors. Based on the data from the ongoing Phase 1/2 clinical trial Genmab intends to broaden the development plans for Rina-S within ovarian cancer and other FRα-expressing solid tumors. In January 2024, the U.S. FDA granted Fast Track designation to Rina-S for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.In addition to payment of USD 1.72 billion (DKK 11.80 billion) for all of the outstanding shares of ProfoundBio, Genmab also made a USD 199 million (DKK 1,368 million) payment to holders of outstanding ProfoundBio equity awards for settlement of such vested and non-vested awards. Of the USD 199 million (DKK 1,368 million) payment, USD 187 million (DKK 1,289 million) related to the portion of awards where the vesting period was completed prior to the Acquisition Date. This portion of the payment was therefore determined to be attributable to the pre-combination period and included in purchase consideration. The remaining USD 11 million (DKK 79 million) payment related to the portion of awards with future vesting conditions, and therefore attributable to post-combination services. The amount attributable to the post-combination service does not form part of the consideration and was therefore instead recognized as Acquisition and integration related charges in Genmab’s Consolidated Statements of Comprehensive Income during the second quarter of 2024.The acquisition has been accounted for using the acquisition method of accounting which requires that assets acquired and liabilities assumed be recognized at their fair values as of the Acquisition Date and consolidated into Genmab’s Condensed Consolidated Balance Sheets. The results of operations for ProfoundBio have been included in Genmab’s consolidated financial statements from the Acquisition Date. A fair value measurement has been performed and the purchase price has been allocated to intangible assets, associated deferred tax liabilities, other assets and liabilities, as well as goodwill being the excess value of the purchase price over the fair value of assets acquired and liabilities assumed (the purchase price allocation). The purchase price allocation is considered provisional due to uncertainty on key assumptions which require detailed analysis which has not been possible to conclude as of June 30, 2024. Adjustments may be applied to the purchase price allocation for a period of up to 12 months from the Acquisition Date. The total consideration for the acquisition of ProfoundBio is summarized as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:53.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total Consideration </td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amounts in USD millions</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amounts in DKK millions</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Cash paid for outstanding shares</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 1,718</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 11,798</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Cash for equity compensation attributable to pre-combination service</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 187</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,289</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Total consideration</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 1,905</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 13,087</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Cash acquired</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (122)</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (841)</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Cash used for acquisition of business</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,783</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,246</td></tr></table>The purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the Acquisition Date based upon their respective fair values summarized below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:53.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amounts Recognized as of the Acquisition Date</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amounts in USD millions</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amounts in DKK millions </td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 122</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 841</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Other current assets*</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 4</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 29</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Property and equipment </td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 6</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 41</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">IPR&D</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 1,540</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 10,577</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Technology platform intangible asset</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 181</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 1,243</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Other non-current assets**</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 3</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 21</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Non-current deferred tax liability</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> (297)</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> (2,039)</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Other current liabilities***</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15)</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (108)</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"> Total identifiable net assets</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 1,544</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 10,605</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Goodwill</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 361</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,482</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"> Total consideration</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,905</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,087</td></tr></table>*Includes receivables and other investments**Includes other investments and right-of use assets***Includes other payables, deferred revenue, current deferred tax liability and lease liabilitiesThe carrying values of other current assets, property and equipment, other non-current assets and other current liabilities were determined to approximate their fair values.The fair value assigned to acquired IPR&D, which was calculated using the multi-period excess earnings method of the income approach, was based on the present value of expected after-tax cash flows attributable to Rina-S, which is in Phase 1/2 testing. The present value of expected after-tax cash flows obtainable from Rina-S and assigned to IPR&D was determined by estimating the after-tax costs to complete development of Rina-S into a commercially viable product, estimating future revenue and ongoing expenses to produce, support and sell Rina-S, on an after-tax basis, and discounting the resulting net cash flows to present value. The revenue and costs projections used were reduced based on the probability that compounds at similar stages of development will become commercially viable products. The rate utilized to discount the net cash flows to their present value reflects the risk associated with the future earnings attributable to the intangible asset. Acquired IPR&D will be accounted for as an intangible asset not yet available for use until regulatory approval in a major market is received or development is discontinued.The fair value of the technology platform intangible asset was calculated using the relief from royalty method of the income approach. This method includes assigning value based on the economic savings from owning, rather than in-licensing, the technology platform intangible asset supported by observable market data for peer companies, then discounting the resulting probability adjusted net post-tax cash flows using a discount rate commensurate with the risk associated with the future income or cost savings attributable to the intangible asset.The significant assumptions used to estimate the value of the acquired intangible assets include discount rates and certain assumptions that form the basis of future cash flows (such as probabilities of technical and commercial success, revenue growth rates, operating margins, and royalty rates). The excess of purchase price over the fair value amounts assigned to identifiable assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition. The goodwill recorded as part of the acquisition is attributable to the intangible assets that do not qualify for separate recognition at the time of the acquisition, assembled workforce and deferred tax consequences of the IPR&D and technology platform intangible asset recorded for financial statement purposes. Genmab does not expect any portion of this goodwill to be deductible for tax purposes. The goodwill attributable to the acquisition has been recorded as a non-current asset in Genmab’s Consolidated Balance Sheets and is not amortized, but is subject to review for impairment annually.From the Acquisition Date through June 30, 2024, Genmab’s Condensed Consolidated Statements of Comprehensive Income include no revenue and the following expenses associated with the acquisition and operations of ProfoundBio (in DKK millions):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:35.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;">Consolidated Statements of Comprehensive Income (DKK million):</td><td style="vertical-align:middle;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Acquisition Date through June 30, 2024</td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;">Research and development expenses</td><td style="vertical-align:middle;width:35.89%;margin:0pt;padding:0pt;">70 </td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;">Selling, general and administrative expenses</td><td style="vertical-align:middle;width:35.89%;margin:0pt;padding:0pt;">7 </td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;">Acquisition and integration related charges*</td><td style="vertical-align:middle;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">139 </td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:middle;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">216 </td></tr></table>*Acquisition related charges incurred from the Acquisition Date through June 30, 2024, are comprised of payments to holders of outstanding ProfoundBio equity awards related to post-combination services (DKK 79 million). The remaining expenses are integration related charges incurred from the Acquisition Date through June 30, 2024, which are comprised of professional fees incurred to assist with the integration of ProfoundBio into Genmab’s operations post-acquisition. Additionally, prior to the Acquisition Date, Genmab recorded DKK 113 million in Acquisition and integration related charges in Genmab’s Consolidated Statements of Comprehensive Income related to professional due diligence procedures in connection with the acquisition of ProfoundBio.The following table provides Genmab’s consolidated revenue and net profit for the first six months of 2024 as if the acquisition of ProfoundBio had occurred on January 1, 2024 (in DKK millions):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:35.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:middle;width:35.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Six Month Period Ended June 30, 2024</td></tr><tr><td style="vertical-align:middle;width:64.12%;margin:0pt;padding:0pt;">Revenue</td><td style="vertical-align:middle;width:35.87%;margin:0pt;padding:0pt;"> 9,545</td></tr><tr><td style="vertical-align:middle;width:64.12%;margin:0pt;padding:0pt;">Net Profit</td><td style="vertical-align:middle;width:35.87%;margin:0pt;padding:0pt;"> 2,516</td></tr></table>The unaudited pro forma information does not necessarily reflect the actual results of operations of the combined entities that would have been achieved, nor are they necessarily indicative of future results of operations. The unaudited pro forma information reflects certain adjustments that were directly attributable to the acquisition of ProfoundBio, including additional amortization adjustments for the fair value of the technology platform intangible asset acquired.As of June 30, 2024, Cash and cash equivalents in Genmab’s Consolidated Balance Sheets includes USD 30 million (DKK 210 million) of restricted cash balances for funds held in escrow related to the acquisition of ProfoundBio.

3 1720000000 11800000000 199000000 1368000000 199000000 1368000000 187000000 1289000000 11000000 79000000

<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:53.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total Consideration </td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amounts in USD millions</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amounts in DKK millions</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Cash paid for outstanding shares</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 1,718</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 11,798</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Cash for equity compensation attributable to pre-combination service</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 187</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,289</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Total consideration</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 1,905</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 13,087</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Cash acquired</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (122)</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (841)</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Cash used for acquisition of business</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,783</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,246</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:53.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amounts Recognized as of the Acquisition Date</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amounts in USD millions</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amounts in DKK millions </td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 122</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 841</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Other current assets*</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 4</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 29</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Property and equipment </td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 6</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 41</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">IPR&D</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 1,540</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 10,577</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Technology platform intangible asset</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 181</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 1,243</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Other non-current assets**</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 3</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 21</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Non-current deferred tax liability</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> (297)</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> (2,039)</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Other current liabilities***</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15)</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (108)</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"> Total identifiable net assets</td><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"> 1,544</td><td style="vertical-align:middle;width:27.82%;margin:0pt;padding:0pt;"> 10,605</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;">Goodwill</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 361</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,482</td></tr><tr><td style="vertical-align:middle;width:46.26%;margin:0pt;padding:0pt;"> Total consideration</td><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,905</td><td style="vertical-align:middle;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,087</td></tr></table>*Includes receivables and other investments**Includes other investments and right-of use assets***Includes other payables, deferred revenue, current deferred tax liability and lease liabilitiesFrom the Acquisition Date through June 30, 2024, Genmab’s Condensed Consolidated Statements of Comprehensive Income include no revenue and the following expenses associated with the acquisition and operations of ProfoundBio (in DKK millions):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:35.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;">Consolidated Statements of Comprehensive Income (DKK million):</td><td style="vertical-align:middle;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Acquisition Date through June 30, 2024</td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;">Research and development expenses</td><td style="vertical-align:middle;width:35.89%;margin:0pt;padding:0pt;">70 </td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;">Selling, general and administrative expenses</td><td style="vertical-align:middle;width:35.89%;margin:0pt;padding:0pt;">7 </td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;">Acquisition and integration related charges*</td><td style="vertical-align:middle;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">139 </td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:middle;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">216 </td></tr></table>*Acquisition related charges incurred from the Acquisition Date through June 30, 2024, are comprised of payments to holders of outstanding ProfoundBio equity awards related to post-combination services (DKK 79 million). The remaining expenses are integration related charges incurred from the Acquisition Date through June 30, 2024, which are comprised of professional fees incurred to assist with the integration of ProfoundBio into Genmab’s operations post-acquisition. Additionally, prior to the Acquisition Date, Genmab recorded DKK 113 million in Acquisition and integration related charges in Genmab’s Consolidated Statements of Comprehensive Income related to professional due diligence procedures in connection with the acquisition of ProfoundBio.The following table provides Genmab’s consolidated revenue and net profit for the first six months of 2024 as if the acquisition of ProfoundBio had occurred on January 1, 2024 (in DKK millions):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:35.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:middle;width:35.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Six Month Period Ended June 30, 2024</td></tr><tr><td style="vertical-align:middle;width:64.12%;margin:0pt;padding:0pt;">Revenue</td><td style="vertical-align:middle;width:35.87%;margin:0pt;padding:0pt;"> 9,545</td></tr><tr><td style="vertical-align:middle;width:64.12%;margin:0pt;padding:0pt;">Net Profit</td><td style="vertical-align:middle;width:35.87%;margin:0pt;padding:0pt;"> 2,516</td></tr></table>

1718000000 11798000000 187000000 1289000000

1905000000

13087000000

122000000

841000000

1783000000

12246000000

122000000

841000000

4000000 29000000

6000000

41000000

1540000000

10577000000

181000000

1243000000

3000000 21000000

297000000

2039000000

-15000000 -108000000

1544000000

10605000000

361000000

2482000000

1905000000

13087000000

70000000 7000000 139000000 216000000 79000000

113000000

9545000000

2516000000

30000000

210000000

Note 3 – Revenue The table below summarizes Genmab’s revenue by type and collaboration partner, and royalties by product, under Genmab’s agreements.<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.21%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.73%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.21%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.73%;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Revenue by type:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Royalties</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 4,569</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 3,478</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 7,673</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 5,886</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Reimbursement revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 289</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 228</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 569</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 483</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Milestone revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 351</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 343</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 455</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Collaboration revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 113</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 73</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 206</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 140</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Net product sales</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 431</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 754</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,402</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,169</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,545</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,003</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Revenue by collaboration partner:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Janssen</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 3,844</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 2,974</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 6,323</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 5,054</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Roche</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 161</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 170</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 342</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 336</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Novartis</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 558</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 337</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 999</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 606</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">BioNTech</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 259</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 216</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 509</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 446</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Pfizer</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 137</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 85</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 256</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 174</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">AbbVie</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 348</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 362</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 348</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Total*</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,971</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,130</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,791</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,964</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Royalties by product:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">DARZALEX </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 3,731</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 2,923</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 6,113</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 4,855</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Kesimpta </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 553</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 334</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 990</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 600</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">TEPEZZA </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 161</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 170</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 342</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 336</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Other**</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 124</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 51</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 228</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 95</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,569</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,478</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,673</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,886</td></tr></table>* Excludes Genmab’s Net product sales** Other consist of royalties from net sales of RYBREVANT, TECVAYLI, TALVEY and TEPKINLY. Net Product SalesGenmab recognized net product sales of DKK 754 million during the first six months of 2024 compared to DKK 39 million in the first six months of 2023. EPKINLY was approved in the U.S. in May 2023 and Japan in September 2023. Deferred RevenueAs part of the continued evaluation of deferred revenue related to the AbbVie Agreement, during the first six months of 2024, Genmab’s classification of deferred revenue reflects the current estimate of co-development activities as of June 30, 2024, with no deferred revenue recognized as revenue. These co-development activities are related to a performance obligation in connection with the product concepts under a research option agreement.Refer to Note 2.1 in the Annual Report for further details regarding revenue.

<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.21%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.73%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.21%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.73%;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Revenue by type:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Royalties</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 4,569</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 3,478</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 7,673</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 5,886</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Reimbursement revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 289</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 228</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 569</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 483</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Milestone revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 351</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 343</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 455</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Collaboration revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 113</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 73</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 206</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 140</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Net product sales</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 431</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 754</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,402</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,169</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,545</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,003</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Revenue by collaboration partner:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Janssen</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 3,844</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 2,974</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 6,323</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 5,054</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Roche</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 161</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 170</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 342</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 336</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Novartis</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 558</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 337</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 999</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 606</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">BioNTech</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 259</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 216</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 509</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 446</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Pfizer</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 137</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 85</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 256</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 174</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">AbbVie</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 348</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 362</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 348</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Total*</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,971</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,130</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,791</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,964</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Royalties by product:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">DARZALEX </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 3,731</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 2,923</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 6,113</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 4,855</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Kesimpta </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 553</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 334</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 990</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 600</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">TEPEZZA </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 161</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"> 170</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;margin:0pt;padding:0pt;"> 342</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 336</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Other**</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 124</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 51</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 228</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 95</td></tr><tr><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,569</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,478</td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,673</td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,886</td></tr></table>

4569000000

3478000000

7673000000

5886000000

289000000

228000000

569000000

483000000

351000000

343000000

455000000

113000000

73000000

206000000

140000000

431000000

39000000

754000000

39000000

5402000000

4169000000

9545000000

7003000000

3844000000 2974000000 6323000000 5054000000 161000000 170000000 342000000 336000000 558000000 337000000 999000000 606000000 259000000 216000000 509000000 446000000 137000000 85000000 256000000 174000000 12000000 348000000 362000000 348000000 4971000000 4130000000 8791000000 6964000000

3731000000

2923000000

6113000000

4855000000

553000000

334000000

990000000

600000000

161000000

170000000

342000000

336000000

124000000

51000000

228000000

95000000

4569000000

3478000000

7673000000

5886000000

754000000

39000000

Note 4 – Intangible Assets & Goodwill<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:42.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:bottom;width:16.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gross Carrying Value</td><td style="vertical-align:bottom;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Accumulated Amortization</td><td style="vertical-align:bottom;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Impairment</td><td style="vertical-align:bottom;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Intangible Assets, Net</td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">June 30, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">Amortizable Intangible Assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">Licenses & Patents</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"> 912</td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"> (817)</td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"> (64)</td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"> 31</td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">Technology Platform</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,261</td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9)</td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> -</td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,252</td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"> 2,173</td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"> (826)</td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"> (64)</td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"> 1,283</td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">Non-amortized Intangible Assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">Acquired IPR&D Rights</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,728</td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> -</td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> -</td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,728</td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">Total Intangible Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,901</td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (826)</td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (64)</td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,011</td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">December 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">Amortizable Intangible Assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">Licenses & Patents</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 901</td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (800)</td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> -</td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 101</td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;">Total Intangible Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:16.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 901</td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (800)</td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> -</td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 101</td></tr></table>Intangible AssetsThe increase in the gross carrying value of intangible assets during the first six months of 2024 was primarily due to the addition of approximately DKK 10,728 million of IPR&D and DKK 1,261 million of a technology platform asset from the ProfoundBio acquisition. The technology platform asset is being amortized over its estimated useful life of 15 years. Refer to Note 2 for additional details.Amortization expense was DKK 26 million and DKK 27 million for the first six months of 2024 and 2023, respectively, which was recorded in Research and development expenses in the Condensed Consolidated Statements of Comprehensive Income GoodwillThe carrying amount of goodwill was DKK 2,518 million as of June 30, 2024 due to the acquisition of ProfoundBio (refer to Note 2). There was no goodwill balance as of December 31, 2023.

912000000

-817000000

-64000000

31000000

1261000000

-9000000

1252000000

2173000000

-826000000

-64000000

1283000000

10728000000

12901000000

-826000000

-64000000

12011000000

901000000

-800000000

101000000

901000000

-800000000

101000000

10728000000

1261000000

P15Y

26000000

27000000

2518000000

Note 5 – Financial Instruments Genmab’s portfolio is spread over a number of different securities with a focus on liquidity and the preservation of capital. Genmab’s marketable securities in USD, DKK, EUR, and GBP as a percentage of total marketable securities was as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.04%;background:#e6e6e6;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.65%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.04%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">Percent</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">USD</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;margin:0pt;padding:0pt;"> 78</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"> 81</td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">DKK</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;margin:0pt;padding:0pt;"> 13</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"> 12</td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">EUR</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;margin:0pt;padding:0pt;"> 8</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"> 6</td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">GBP</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1</td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 100</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 100</td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">%</td></tr></table>As of June 30, 2024, 70% of Genmab’s marketable securities were long-term A rated or higher, or short-term A-1 / P-1 rated compared to 72% as of December 31, 2023.The table below shows the fair value measurements by level for Genmab’s financial assets measured at fair value through profit or loss:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.56%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, 2024</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2023</td></tr><tr><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Assets Measured at Fair Value</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.34%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td></tr><tr><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.34%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.91%;margin:0pt;padding:0pt;">Marketable securities</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"> 11,402</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#e7e6e6;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;background:#e7e6e6;margin:0pt;padding:0pt;"> 11,402</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;">13,268</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;">13,268</td></tr><tr><td style="vertical-align:bottom;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Other investments</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 38</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 144</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 196</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">47</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">87</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">134</td></tr></table>Marketable SecuritiesAll fair values are determined by reference to external sources using unadjusted quoted prices in established markets for Genmab’s marketable securities (Level 1). Other InvestmentsOther investments primarily consist of investments in certain strategic investment funds. Genmab’s share of the fair value of these fund investments is determined based on the valuation of the underlying investments included in the fund. Investments in publicly traded equity securities included in these strategic investment funds are valued based at the most recent sale price or official closing price reported on the exchange or over-the-counter market on which they trade, while investments in non-publicly traded equity securities are based on other factors, including but not limited to, type of the security, the size of the holding, the initial cost of the security, the price and extent of public trading in similar securities of the comparable companies, an analysis of the company's or issuer's financial statements and with respect to debt securities, the maturity and creditworthiness. As such, these fund investments have been characterized as Level 3 investments as fair values are not entirely based on observable market data. Refer to Note 4.3 and Note 4.4 in the Annual Report for further details regarding Genmab’s marketable securities and other investments.

<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.04%;background:#e6e6e6;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.65%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.04%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">Percent</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">USD</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;margin:0pt;padding:0pt;"> 78</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"> 81</td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">DKK</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;margin:0pt;padding:0pt;"> 13</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"> 12</td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">EUR</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;margin:0pt;padding:0pt;"> 8</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"> 6</td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">GBP</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1</td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 100</td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 100</td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">%</td></tr></table> 0.78 0.81 0.13 0.12 0.08 0.06 0.01 0.01 1 1 0.70 0.72 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.56%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, 2024</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2023</td></tr><tr><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Assets Measured at Fair Value</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.34%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td></tr><tr><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.34%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:25.91%;margin:0pt;padding:0pt;">Marketable securities</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"> 11,402</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#e7e6e6;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;background:#e7e6e6;margin:0pt;padding:0pt;"> 11,402</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;">13,268</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;">13,268</td></tr><tr><td style="vertical-align:bottom;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Other investments</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 38</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 144</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 196</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">47</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">87</td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">134</td></tr></table>

11402000000

13268000000

38000000

14000000

144000000

196000000

47000000

87000000

134000000

Note 6 – Financial Income and Expenses<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Financial income:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Interest and other financial income</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 292</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 227</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 609</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 428</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Gain on marketable securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 85</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 86</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 218</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 248</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Gain on other investments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 114</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 33</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 121</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 62</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Foreign exchange rate gain</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 395</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> -</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,045</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Total financial income</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 886</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 346</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,993</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 738</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Financial expenses:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Interest and other financial expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (19)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (25)</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (48)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (40)</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Loss on marketable securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (39)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (82)</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (129)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (159)</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Loss on other investments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (85)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (3)</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (98)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (25)</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Foreign exchange rate loss</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (256)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10)</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (316)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (439)</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Total financial expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (399)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (120)</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (591)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (663)</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Net financial items</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 487</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 226</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,402</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75</td></tr></table>Interest IncomeInterest income was DKK 609 million in the first six months of 2024 compared to DKK 428 million in the first six months of 2023. The increase of DKK 181 million was driven by higher cash and cash equivalents and marketable securities, as well as higher interest rates on USD denominated marketable securities in the first six months of 2024 compared to the first six months of 2023.Foreign Exchange Rate Gains and LossesForeign exchange rate gain, net was DKK 729 million, comprised of DKK 1,045 million foreign exchange rate gains, offset by DKK 316 million foreign exchange rate losses in the first six months of 2024 compared to foreign exchange rate loss of DKK 439 million in the first six months of 2023. The USD strengthened against the DKK in the first six months of 2024, positively impacting our USD denominated securities and cash holdings. The USD weakened against the DKK in the first six months of 2023, negatively impacting our USD denominated securities and cash holdings.<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:12.51%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;">USD/DKK Foreign Exchange Rates</td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:12.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6.9664</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">6.7447</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">6.8539</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">6.9722</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:12.51%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;">% Increase/(decrease) from prior year-end</td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:12.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">3.3%</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(1.7)%</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"></td></tr></table>

<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Financial income:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Interest and other financial income</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 292</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 227</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 609</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 428</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Gain on marketable securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 85</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 86</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 218</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 248</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Gain on other investments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 114</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 33</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> 121</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> 62</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Foreign exchange rate gain</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 395</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> -</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,045</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Total financial income</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 886</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 346</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,993</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 738</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Financial expenses:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Interest and other financial expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (19)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (25)</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (48)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (40)</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Loss on marketable securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (39)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (82)</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (129)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (159)</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Loss on other investments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (85)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (3)</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"> (98)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> (25)</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Foreign exchange rate loss</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (256)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10)</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (316)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (439)</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Total financial expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (399)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (120)</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (591)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (663)</td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:39.75%;margin:0pt;padding:0pt;">Net financial items</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 487</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 226</td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.46%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,402</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75</td></tr></table> 292000000 227000000 609000000 428000000 85000000 86000000 218000000 248000000 114000000 33000000 121000000 62000000

395000000

1045000000

886000000

346000000

1993000000

738000000

19000000 25000000 48000000 40000000 39000000 82000000 129000000 159000000 85000000 3000000 98000000 25000000

256000000

10000000

316000000

439000000

399000000

120000000

591000000

663000000

487000000

226000000

1402000000

75000000

609000000 428000000 181000000

729000000

1045000000

316000000

439000000

6.9664

6.7447

6.8539

6.9722

0.033 -0.017

Note 7 – Share-Based PaymentsRestricted Stock Unit ProgramGenmab has established an RSU program (equity-settled share-based payment transactions) as an incentive for Genmab’s employees, members of the Executive Management, and members of the Board of Directors. RSUs granted to Executive Management are performance-based.<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.96%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.96%;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.88%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.71%;margin:0pt;padding:0pt;">RSUs granted</td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.88%;background:#e7e6e6;margin:0pt;padding:0pt;"> 452,485</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.88%;margin:0pt;padding:0pt;"> 281,061</td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:60.71%;margin:0pt;padding:0pt;">Weighted average fair value per RSU granted (DKK) </td><td style="vertical-align:middle;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:16.88%;background:#e7e6e6;margin:0pt;padding:0pt;"> 2,010.05</td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:16.88%;margin:0pt;padding:0pt;"> 2,640.65</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.88%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.88%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.71%;margin:0pt;padding:0pt;">RSUs vested</td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 130,579</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 87,719</td></tr></table>Refer to Note 4.6 in the Annual Report for details on the RSU program.Warrant ProgramGenmab has established a warrant program (equity-settled share-based payment transactions) as an incentive for all Genmab employees. Following Genmab’s Annual General Meeting on March 29, 2023, members of the registered Executive Management and members of the Board of Directors may only be granted RSUs.<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.17%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.17%;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.28%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;">Warrants granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.28%;background:#e7e6e6;margin:0pt;padding:0pt;"> 345,079</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"> 193,853</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;">Weighted average exercise price per warrant granted (DKK) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.28%;background:#e7e6e6;margin:0pt;padding:0pt;"> 2,006.50</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"> 2,657.01</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;">Weighted average Black-Scholes fair value per warrant granted (DKK) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.28%;background:#e7e6e6;margin:0pt;padding:0pt;"> 650.72</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"> 937.43</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.28%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;">Warrants exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.28%;background:#e7e6e6;margin:0pt;padding:0pt;"> 62,374</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"> 76,852</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;">Weighted average exercise price on date of grant per warrant exercised (DKK)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.28%;background:#e7e6e6;margin:0pt;padding:0pt;"> 1,208.46</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"> 1,337.58</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;">% change in share capital - warrants exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.28%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">0.09%</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">0.12%</td></tr></table>Refer to Note 4.6 in the Annual Report for details on the warrant program.Share-Based Compensation ExpenseShare-based compensation expenses related to Genmab’s RSU and warrant programs for the first six months of 2024 were DKK 349 million compared to DKK 271 million for the first six months of 2023. Share RepurchasesAs of June 30, 2024, Genmab’s 2021 and 2023 authorizations have shares available for repurchase, whereas Genmab’s 2019 authorization has expired. In addition, at Genmab’s Annual General Meeting on March 13, 2024, a new authorization to acquire treasury shares up to a nominal amount of DKK 3,500,000 was granted.<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:15.17%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024 Authorization</td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:12.68%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023 Authorization</td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:12.68%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021 Authorization</td><td style="vertical-align:bottom;width:0.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.58%;margin:0pt;padding:0pt;">Number of shares authorized for repurchase1</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#e7e6e6;margin:0pt;padding:0pt;"> 3,500,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;margin:0pt;padding:0pt;"> 500,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;margin:0pt;padding:0pt;"> 500,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.58%;margin:0pt;padding:0pt;">Actual shares repurchased under authorization</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#e7e6e6;margin:0pt;padding:0pt;"> 1,821,853</td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;margin:0pt;padding:0pt;"> 450,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.58%;margin:0pt;padding:0pt;">Shares available for repurchase as of June 30, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,678,147</td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 500,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 50,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:72.72%;margin:0pt;padding:0pt;">1 Nominal value of DKK 3,500,000 for 2024, and DKK 500,000 for 2023 and 2021 Authorizations</td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"></td></tr></table>As announced on February 14, 2024, and March 15, 2024, Genmab initiated two share buy-back programs. The purpose of the share buy-back program announced on February 14, 2024, was to honor Genmab’s commitments under the RSU program. The share buy-back program announced on March 15, 2024, was in support of Genmab’s capital allocation strategy. During the first six months of 2024, Genmab acquired 2,011,853 of its own shares under both programs, representing approximately 3.0% of share capital as of December 31, 2023. The total amount incurred to acquire the shares, including directly attributable costs, was DKK 3,879 million and was recognized as a deduction to shareholders’ equity. These shares are classified as treasury shares and are presented within retained earnings on the Consolidated Balance Sheets as of June 30, 2024. During the first six months of 2023, Genmab acquired 220,000 of its own shares, representing approximately 0.3% of share capital as of December 31, 2022. The total amount incurred to acquire the shares, including directly attributable costs, was DKK 564 million and was recognized as a deduction to shareholders’ equity.As of June 30, 2024, 2,670,991 treasury shares were held by Genmab.

452485

281061

2010.05 2640.65

130579

87719

349000000

271000000

3500000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:15.17%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024 Authorization</td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:12.68%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023 Authorization</td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:12.68%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021 Authorization</td><td style="vertical-align:bottom;width:0.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.58%;margin:0pt;padding:0pt;">Number of shares authorized for repurchase1</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#e7e6e6;margin:0pt;padding:0pt;"> 3,500,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;margin:0pt;padding:0pt;"> 500,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;margin:0pt;padding:0pt;"> 500,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.58%;margin:0pt;padding:0pt;">Actual shares repurchased under authorization</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#e7e6e6;margin:0pt;padding:0pt;"> 1,821,853</td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;margin:0pt;padding:0pt;"> 450,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.58%;margin:0pt;padding:0pt;">Shares available for repurchase as of June 30, 2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,678,147</td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 500,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 50,000</td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:72.72%;margin:0pt;padding:0pt;">1 Nominal value of DKK 3,500,000 for 2024, and DKK 500,000 for 2023 and 2021 Authorizations</td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"></td></tr></table> 3500000 500000 500000 1821853 450000 1678147 500000 50000 3500000 500000 500000 2 2 2011853 0.030

3879000000

220000 0.003

564000000

2670991

Note 8 – Related PartiesGenmab’s related parties are its Board of Directors, Executive Management, and close members of the family of these persons. Genmab has not granted any loans, guarantees or other commitments to or on behalf of any of the members of the Board of Directors or members of the Executive Management.Other than the similar remuneration relating to the Board of Directors and the Executive Management described in Note 5.1 in the Annual Report, there were no material related party transactions during the first six months of 2024.Following Genmab’s Annual General Meeting on March 13, 2024, the Board of Directors is comprised of five independent board members, one non-independent board member, and three employee-elected board members. Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Elizabeth O’Farrell, Paolo Paoletti and Anders Gersel Pedersen were re-elected to the Board of Directors for a one-year period. Mijke Zachariasse, Martin Schultz and Takahiro Hamatani continue to serve as employee-elected board members for a three-year period expiring in 2025.

5 1 3 P3Y

Note 9 – LeasesAmounts recognized in the Condensed Consolidated Balance SheetsThe Consolidated Balance Sheets show the following amounts relating to leases:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;">Right-of-use assets</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;">Properties</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 928</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 686</td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;">Total right-of-use assets</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 928</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 686</td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;">Lease liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;">Current</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"> 94</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"> 90</td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;">Non-current</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 925</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 680</td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;">Total lease liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,019</td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 770</td></tr></table>During the first six months of 2024, there were additions to Genmab’s right-of-use assets and lease liabilities related to the commencement of leases in the U.S. with respect to office and laboratory space and in Japan with respect to office space. During the first six months of 2023, there were additions to Genmab’s right-of-use assets and lease liabilities related to the commencement of a lease for the new headquarters in Denmark. Amounts recognized in the Condensed Consolidated Statements of Comprehensive IncomeThe Consolidated Statements of Comprehensive Income show the following amounts relating to leases:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.34%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.79%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.34%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.79%;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;">(DKK million)</td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;">Depreciation charge of right-of-use assets</td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;">Properties</td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#e6e6e6;margin:0pt;padding:0pt;"> 26</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> 23</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#e6e6e6;margin:0pt;padding:0pt;"> 48</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"> 44</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;">Total depreciation charge of right-of-use assets</td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#e7e6e6;margin:0pt;padding:0pt;"> 26</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> 23</td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#e7e6e6;margin:0pt;padding:0pt;"> 48</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"> 44</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#e7e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#e6e6e6;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"></td></tr></table>Variable lease payments, short-term lease expense, lease interest expense and low-value leases are not material.

928000000

686000000

928000000

686000000

94000000

90000000

925000000

680000000

1019000000

770000000

26000000

23000000

48000000

44000000

26000000

23000000

48000000

44000000

Note 10 – ContingencyIn 2024, Chugai filed a lawsuit in the Tokyo District Court, Japan against AbbVie’s and Genmab’s subsidiaries in Japan asserting that their activities with EPKINLY (epcoritamab) in Japan infringe two Japanese patents held by Chugai, JP6278598 and JP6773929. Chugai is claiming damages and injunctive relief. Genmab and AbbVie believe that the two Japanese patents are invalid and not infringed and intend to vigorously defend against the lawsuit, and thus no provision has been recorded related to this matter.

2 2

Note 11 – Subsequent Events to the Balance Sheet DateNo events have occurred subsequent to the balance sheet date that could significantly affect the financial statements as of June 30, 2024.